High Blood Pressure & Cardiovascular Prevention, Год журнала: 2024, Номер 31(3), С. 289 - 297
Опубликована: Май 13, 2024
Prevalence of cardiac and vascular fibrosis in patients with Idiopathic Pulmonary Fibrosis (IPF) has not been extensively evaluated.
Язык: Английский
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(6), С. 3086 - 3086
Опубликована: Март 7, 2024
Diabetic kidney disease (DKD) is a major cause of chronic (CKD), and it heightens the risk cardiovascular incidents. The pathogenesis DKD thought to involve hemodynamic, inflammatory, metabolic factors that converge on fibrotic pathway. Genetic predisposition unhealthy lifestyle practices both play significant role in development progression DKD. In spite recent emergence angiotensin receptors blockers (ARBs)/angiotensin converting enzyme inhibitor (ACEI), sodium-glucose cotransporter 2 (SGLT2) inhibitors, nonsteroidal mineralocorticoid antagonists (NS-MRAs), current therapies still fail effectively arrest Glucagon-like peptide 1 receptor agonists (GLP-1RAs), promising class agents, possess potential act as renal protectors, slowing Other including pentoxifylline (PTF), selonsertib, baricitinib hold great promise for due their anti-inflammatory antifibrotic properties. Multidisciplinary treatment, encompassing modifications drug therapy, can decelerate Based treatment heart failure, recommended use multiple drugs combination rather than single-use Unearthing mechanisms underlying urgent optimize management Inflammatory (including IL-1, MCP-1, MMP-9, CTGF, TNF-a TGF-β1), along with lncRNAs, not only serve diagnostic biomarkers, but also therapeutic targets. this review, we delve into We explore additional value combing these develop novel strategies. Drawing from understanding pathogenesis, propose HIF AGE epigenetic targets future.
Язык: Английский
Процитировано
23
Molecular and Cellular Biochemistry, Год журнала: 2025, Номер unknown
Опубликована: Янв. 7, 2025
Язык: Английский
Процитировано
0
Molecular Biotechnology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 13, 2025
Язык: Английский
Процитировано
0
Molecular Biotechnology, Год журнала: 2025, Номер unknown
Опубликована: Март 14, 2025
Язык: Английский
Процитировано
0
Cardiac Surgery and Interventional Cardiology, Год журнала: 2025, Номер 14(1), С. 35 - 43
Опубликована: Март 29, 2025
The aim – to analyze and summarize experimental clinical data on the cardio- vasoprotective mechanisms of zofenopril determine its significance in patients with high cardiovascular riskAn analytical review literature antioxidant, anti-ischemic, anti-inflammatory effects was conducted. results long-term SMILE research program, which investigated effect course acute myocardial infarction, left ventricular dysfunction, ischemia, were also analyzed. Zofenopril exhibits pronounced antioxidant activity, reducing oxidative stress free oxygen radicals. By increasing bioavailability NO H2S, it mitigates ischemic damage, improves endothelial function, enhances vasodilation. inhibits atherosclerosis progression, prevents intimal hyperplasia, reduces ischemia–reperfusion injury myocardium, positively affects arterial stiffness. In a series trials, shown reduce both hospitalization rates mortality following including those dysfunction. Compared other ACE inhibitors, is characterized by favorable safety profile additional cardioprotective benefits.Conclusions. combination properties makes an effective safe agent for treatment hypertension heart disease. use outcomes quality life these patients.
Язык: Английский
Процитировано
0
High Blood Pressure & Cardiovascular Prevention, Год журнала: 2024, Номер 31(3), С. 289 - 297
Опубликована: Май 13, 2024
Prevalence of cardiac and vascular fibrosis in patients with Idiopathic Pulmonary Fibrosis (IPF) has not been extensively evaluated.
Язык: Английский
Процитировано
1